Profluent Secures $106M Funding to Enhance AI-Driven Biology Solutions

Profluent, a frontrunner in the application of frontier AI for protein design, has successfully raised $106 million in a financing round co-led by Altimeter Capital and Bezos Expeditions. This funding, which includes contributions from existing investors such as Spark Capital, Insight Partners, and Air Street Capital, elevates Profluent's total funding to $150 million. The company aims to enhance its mission of making biology programmable, significantly transforming the development of therapeutics, diagnostics, agriculture, and biomanufacturing solutions.

Profluent is leading the charge in utilizing large-scale frontier AI models for protein design. The company has made significant strides since its inception, being the first to show that large language models can generate functional proteins (Nature Biotech, 2023), designing the first CRISPR system entirely from AI (Nature, 2025), and proving that scaling laws are applicable to protein design (NeurIPS spotlight, 2025). Their Protein Atlas now holds over 115 billion unique proteins, making it the largest protein data resource globally.

The AI-designed molecules and foundational models developed by Profluent are already in use across various sectors, including pharmaceuticals and biotechnology. OpenCRISPR-1, the company's open-source gene editor, is employed by thousands of commercial entities, academic researchers, and major pharmaceutical companies. Profluent has established commercial partnerships with industry leaders such as Revvity, Corteva Agrisciences, The Rett Syndrome Research Trust, and Integrated DNA Technologies, Inc. This growth reflects a broader trend where the scaling of models corresponds with an expanding design space and an increasing number of commercially viable protein products.

“With this funding, we are accelerating the path from lab breakthroughs to real-world applications, creating bespoke proteins to solve challenges in human health and the environment,” said Ali Madani, Ph.D., Profluent founder and Chief Executive Officer. “Partners are already deploying our technology while our R&D efforts are rapidly expanding the range and depth of our design capabilities. This capital enables Profluent to expand our platform’s capabilities, expand markets, and bring abundance to therapeutics, agriculture, and biomanufacturing.”

Profluent has broadened its commercial focus beyond genome editors to include antibodies, antigens, enzymes, and other biologic formats. The success of its genome editors has mitigated risks associated with the platform, positioning Profluent as the preferred partner across various industries for protein design and optimization. This strategy is paving the way for the introduction of AI-designed therapeutics to human patients.

“Profluent combines world-class AI, biology and therapeutic development expertise against the backdrop of thriving scaling laws,” remarked Jamin Ball, partner at Altimeter Capital. “This positions them not just as a frontier science company, but as the foundation of a massive new industry. Programmable biology opens the largest design space in nature and reaches into multi-trillion-dollar markets, and Profluent is only at the beginning of exploring it.”